曲妥珠单抗联合化疗在HER-2阳性转移性乳腺癌中的应用效果观察

The application observation of trastuzumab combined with chemotherapy in HER-2 positive metastatic breast cancer

目的观察曲妥珠单抗联合化疗在HER-2阳性转移性乳腺癌中的应用效果。方法 2008年10月～2011年10月,52例HER-2阳性转移性乳腺癌患者随机分为两组,观察组29例采用曲妥珠单抗联合化疗治疗,对照组23例仅采用化疗治疗,对比观察两组的临床疗效及不良反应。结果观察组RR、DCR率为41.4%、75.9%,明显高于对照组,差异有统计学意义(P<0.05)。两组白细胞下降、胃肠道反应、肝功能损害、心脏毒性和关节肌肉痛发生率比较,差异无统计学意义(P>0.05)。结论曲妥珠单抗联合化疗对HER-2阳性转移性乳腺癌患者进行治疗,能够明显提高疗效,并且不会增加不良反应的发生,值得临床推广应用。

Objective To observe the application of trastuzumab combined with chemotherapy in HER-2 positive meta- static breast cancer. Methods From October 2008 to October 2011,52 cases of HER-2 positive metastatic breast cancer patients were randomly divided into two groups, which observation group with 29 cases was treated with trastuzumab combined with chemo- therapy and control group with 23 cases was treated with chemotherapy. The clinical effect and adverse reaction between two groups were observed and compared. Results The RR and DCR rates were 41.4% ,75. 9% , which were significantly higher than those in control group （P 〈 0. 05 ）. the incidences of leukopenia, gastrointestinal reactions, liver dysfunction, cardiac toxicity, and joint and muscle pain between two groups were no significant differences （ P 〉 0.05 ）. Conclusion trastuzumab combined with chemo- therapy in HER-2 positive metastatic breast cancer can enhance clinical effect, and not increase the adverse reaction, which can be applied in clinic.